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Abstract
Speciﬁc single-nucleotide polymorphisms (SNPs) are recognized as important DNA sequence variations inﬂuencing the pathogenesis of
Pneumocystis jirovecii and the clinical outcome of Pneumocystis pneumonia, which is a major worldwide cause of illness among immuno-
compromised patients. Genotyping platforms for pooled DNA samples are promising methodologies for genetic characterization of
infectious organisms. We have developed a new typing strategy for P. jirovecii, which consisted of DNA pools prepared according to
clinical data (HIV diagnosis, microscopic and molecular detection of P. jirovecii, parasite burden, clinical diagnosis and follow-up of infec-
tion) from individual samples using quantitative real-time PCR followed by multiplex-PCR/single base extension (MPCR/SBE). The fre-
quencies of multiple P. jirovecii SNPs (DHFR312, mt85, SOD215 and SOD110) encoded at three distinct loci, the dihydrofolate reductase
(DHFR), the mitochondrial large-subunit rRNA (mtLSU rRNA) and the superoxide dismutase (SOD) loci, were estimated in seven DNA
pooled samples, representing a total of 100 individual samples. The studied SNPs were conﬁrmed to be associated with distinct clinical
parameters of infection such as parasite burden and follow-up. The MPCR/SBE-DNA pooling methodology, described in the present
study, was demonstrated to be a useful high-throughput procedure for large-scale P. jirovecii SNPs screening and a powerful tool for
evaluation of clinically relevant SNPs potentially related to parasite burden, clinical diagnosis and follow-up of P. jirovecii infection. In fur-
ther studies, the candidate SNPs mt85, SOD215 and SOD110 may be used as molecular markers in association with MPCR/SBE-DNA
pooling to generate useful information for understanding the patterns and causes of Pneumocystis pneumonia.
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Introduction
Pneumocystis jirovecii is recognized as a worldwide pathogenic
fungus that parasitizes the human alveolar epithelium causing
life-threatening interstitial pneumonia, known as Pneumocystis
pneumonia, or pneumocystosis (PcP). This opportunistic
infectious disease inﬂicts severe morbidity and mortality in
immunocompromised patients, especially in those with AIDS
and is therefore of growing importance among non-HIV-
infected subjects who are undergoing immunosuppressive
treatments related to malignancies, connective tissue diseases
or organ transplantation [1–6].
In the absence of a culture system to isolate and maintain
live organisms, efforts to type and characterize P. jirovecii have
relied on PCR-based approaches [7–10]. Single-nucleotide
polymorphisms (SNPs) are increasingly recognized as the
markers of choice to study the population genetics, geograph-
ical distribution, modes of transmission and drug susceptibility
or resistance of speciﬁc P. jirovecii genotypes [7,9,11–23].
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Multiplex ampliﬁcation of genomic DNA associated with sin-
gle base extension (SBE) is a suitable high-throughput meth-
odology for large-scale SNP screening [16,24,25]. Current
genotyping surveys in a large number of samples are still time
consuming methods. Alternatively, DNA pooling is a reliable
genotyping method, in which equal amounts of DNA from a
large number of individual samples are pooled and the SNP
allele frequencies are estimated [26–29].
Dihydrofolate reductase (DHFR), superoxide dismutase
(SOD) and mitochondrial large-subunit rRNA (mtLSU rRNA)
are important genomic regions involved in basic metabolic
mechanisms (folic acid synthesis and drug resistance, protec-
tion against free oxygen radicals and translation) that carry
SNPs reported previously to be associated with clinical data
and outcome of PcP [10,13,14,30–32].
The goals of the present study were to: (i) develop robust
high-throughput methodologies for large-scale P. jirovecii
genetic characterization; and (ii) correlate clinical parameters
of infection such as parasite burden, clinical diagnosis of PcP
and follow-up with genotyping results, using four P. jirovecii
candidate SNPs (DHFR312, mt85, SOD110 and SOD215).
Materials and Methods
Patients and data
In total, 100 pulmonary specimens (19 induced sputa and 81
bronchoalveolar lavage ﬂuids) tested previously and found to be
positive for P. jirovecii (2001–2008) were included in the study.
The pulmonary specimens were obtained from 85 HIV-positive
adult patients (mean age 41 years; range 24–60 years; 56% were
men) and 15 HIV-negative patients (four neonates, four patients
with neoplasia, three organ recipients, and four children
between 2 and 6 years old with no established cause of immu-
nodeﬁciency), living in Lisbon, Portugal, and were collected,
between 2001 and 2008, at two major hospitals (Hospital de
Santa Maria and Hospital de Egas Moniz, Lisbon, Portugal) for
diagnostic purposes, before the patients started their anti-P. ji-
rovecii therapy with trimethoprim–sulfamethoxazole. The BAL
samples were retrieved by washing with 150 mL 0.9% NaCl
from which 30 mL was used for the study of P. jirovecii. The
present study had the approval of the Institutional Review
Boards/Ethical Committees from the involved institutions and
all patients who enrolled gave their informed consent.
Extraction of DNA was performed using a Mini-BeadBeat-
er/guanidinium thiocyanate–silica method, as described previ-
ously [33]. Detection of P. jirovecii organisms was performed
by both indirect immunoﬂuorescence with monoclonal anti-
bodies (IF) (MonoFluoTM kit P. jirovecii; Bio-Rad, Marnes la
Coquette, France) and nested-PCR. The parasite burden was
estimated using the semi-quantitative method of IF and was
deﬁned as: low (no cysts identiﬁed, but positive by nested-
PCR); moderate (one to three cysts in 30 ﬁelds at ·1000);
and high (four to 30 or more cysts in one ﬁeld at ·1000), as
described previously [10,16,30,33].
A clinical diagnosis of PcP was considered when at least two
of the following variables were present: symptoms such as
unproductive cough, fever and dyspnoea; arterial partial pres-
sure of oxygen lower than 65 mmHg; and chest radiographs
presenting ﬁne bilateral, perihilar interstitial shadowing. Posi-
tive follow-up or clinical improvement was considered when
the patient showed a favourable response to anti-P. jirovecii
therapy (trimethoprim–sulfamethoxazole) and survived for at
least 4 weeks after the diagnosis of PcP. Follow-up was consid-
ered negative either when there was a failure to improve clini-
cally after administration of the anti-P. jirovecii therapy
(trimethoprim–sulfamethoxazole) for more than 10 days or
when the patient died during a PcP episode [1,2,11,30].
DNA quantiﬁcation
A DNA pooling technique was developed using a quantitative
ﬂuorescence-based real-time PCR (qPCR) for P. jirovecii DNA
quantiﬁcation that speciﬁcally targets the nuclear single-copy
gene encoding the kexin-like serine protease (KEX1),
described as unique for this organism [34,35]. The qPCR
assays were performed in the 7300 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA), as follows:
2 min at 50C, 10 min at 95C, and 50 ampliﬁcation cycles
of 15 s at 95C and 1 min at 60C using 9 lL DNA sample,
1· reaction buffer (TaqMan Gene Expression Master Mix;
Applied Biosystems), 1· assay mix (TaqMan MGB probes,
FAM dye-labelled; Applied Biosystems), in a 20 lL reaction
volume. This assay comprises unlabelled PCR primers (for-
ward primer 5¢-CAACCCTGTTCCAATGCCTAA-3¢ and
reverse primer 5¢-CAACACCGATTCCACAAACAGT-3¢)
and a dye-labelled (FAM) minor groove binder (MGB) probe
(5¢-TGCTGGTGAAGTAGCTGCCGTTCGA-3¢), as
described previously [34]. The baseline was taken from
cycles three to 15 and the threshold was set at 0.02. In the
present work The Minimum Information for Publication of
Quantitative Real-Time PCR Experiments (MIQE) Guidelines
were followed for qPCR experiments. The use of MIQE
guidelines is intended to standardize the qPCR method, pro-
viding practical rules for the incorporation of minimum con-
sistency standards and encompassing the key assay
parameters for accurate design, documentation and reporting
of the experimental procedure [36,37].
The qPCR was designed for absolute quantiﬁcation of P. ji-
rovecii DNA in pulmonary specimens, so the exact quantities
of P. jirovecii DNA in each sample were calculated by com-
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paring the results of absolute quantiﬁcation with a standard
P. jirovecii DNA pattern. For this purpose, a PCR targeting
the P. jirovecii KEX1 locus was applied in 15 positive controls
(positive for P. jirovecii by nested-PCR and IF). The KEX1
gene was ampliﬁed using an annealing temperature of 61.5C
and the primers Kex1Fw1 and Kex1Fw2, as reported previ-
ously [35]. The PCR products were analysed by electropho-
retic separation and puriﬁed directly from the agarose gel
(1.5%) using the Jetquick PCR product puriﬁcation spin kit
(Genomed, Wembley, UK). The puriﬁed KEX1 fragments
were combined and mixed in a unique sample. Then, this
standard pattern solution was serially diluted (1:20, 1:40,
1:103, 1:105, 1:5 · 105, 1:106, and 1:5 · 106) and DNA was
quantiﬁed using the PicoGreen dsDNA quantiﬁcation reagent
(Quant-iTTM PicoGreen dsDNA; Invitrogen, Carlsbad, CA).
A bacteriophage k DNA solution with known DNA concen-
tration was diluted (0, 2.5 · 10)4, 2.5 · 10)3, 2.5 · 10)2,
2.5 · 10)1, 2.5, 25 ng/mL). In a 96-well UV Star Microplate
(Greiner Bio-One GmbH, Frickenhausen, Germany), 50 lL
PicoGreen solution (1:200) was added to 50 lL of each sam-
ple, in triplicates. The assays were incubated at room tem-
perature for 1 h and the results were read in the Zenyth
3100 microplate reader (Biochrom Anthos, Cambridge, UK).
A standard curve (DNA concentration versus ﬂuorescence)
was calculated using the ﬂuorescence results of the bacterio-
phage k DNA dilutions. Based on the standard curve, the
DNA concentrations of the P. jirovecii KEX1 pattern serial
dilutions were estimated. Then the quantiﬁcation cycle (Cq)
values of those dilutions were obtained by qPCR, in tripli-
cates. A new standard curve (P. jirovecii KEX1 concentration
versus Cq values) was calculated to determine the quantity of
P. jirovecii DNA in the pulmonary specimens.
DNA pooling
The pulmonary specimens were grouped according to clinical
data (HIV diagnosis, detection of P. jirovecii organisms by IF,
parasite burden, clinical diagnosis of PcP and follow-up), as
follows:
Pool A1: 20 samples from HIV-positive patients with AIDS-
related PcP (positive IF, positive nested-PCR, fulﬁlling clinical
diagnostic criteria for PcP) presenting low parasite burden.
Pool A2: 20 samples from HIV-positive patients with AIDS-
related PcP presenting moderate parasite burden.
Pool A3: 25 samples from HIV-positive patients with AIDS-
related PcP presenting high parasite burden.
Pool B: 20 samples from HIV-positive patients infected with
P. jirovecii and showing an undiagnosed PcP or atypical PcP
presentation (positive IF and nested-PCR, not fulﬁlling clinical
diagnostic criteria for PcP).
Pool C: 15 samples obtained from HIV-negative patients with
proven PcP (positive IF and nested-PCR, fulﬁlling clinical diag-
nostic criteria for PcP).
Another two pools were constituted using 45 samples ran-
domly selected from the HIV-positive patients with AIDS-
related PcP (pools A1, A2 and A3):
Pool D: 25 samples collected from patients with PcP epi-
sodes presenting clinical improvement (positive follow-up).
Pool E: 20 samples collected from patients with PcP who
failed to improve clinically or who died during the PcP epi-
sode (negative follow-up).
For the preparation of the P. jirovecii DNA pooled samples,
individual P. jirovecii samples were diluted (1:20) and the
respective Cq values were estimated using qPCR. The Cq val-
ues were converted into DNA concentrations using the
standard curve P. jirovecii KEX1 concentration versus Cq val-
ues. The P. jirovecii DNA pools were prepared based on the
parameters of infection of the 100 samples studied. Equal
amounts of DNA from each of the individual samples were
proportionally combined in the corresponding pools
(1 · 10)4 ng DNA for pools A1, A2, A3, D and E;
1 · 10)5 ng DNA for pools B and C).
Genotyping
The P. jirovecii DNA pools were studied using a multiplex-
PCR (MPCR)/SBE protocol targeting three polymorphic loci
formerly associated with clinical parameters of infection
(e.g. parasite burden and follow-up), fully described previ-
ously [16]. MPCR/SBE products were analysed by capillary
electrophoretic separation using a CEQ 8000-XL (SNPStart
Master Mix, GenomeLabTM SNPStart Primer Extension Kit;
Beckman Coulter, Brea, CA, USA). The identiﬁcation of the
different MPCR/SBE products was achieved through length
discrimination provided by SBE-TAG probes and the identity
of the SNPs was revealed by the ﬂuorescence of dye-
labelled ddNTP incorporated. Frequencies of SNPs across
pools were estimated in duplicate by calculating the relative
frequencies corresponding to the maximum height of each
SNP peak on the SBE sequencing graphs (35 nucleotides
(nt)—DHFR312, 47 nt—mt85, 64 nt—SOD215 and 75
nt—SOD110) [16]. Reference positive controls (supplied by
the manufacturer) with four ﬂuorochrome control peaks
were used in the SBE assays: 29 nt cytosine (D2—black);
35 nt adenine (D1—red); 36 nt guanine (D3—green); and
50 nt thymine (D4—blue). The maximum height values of
ﬂuorescence peaks observed in the SBE products were
divided by the reference ﬂuorescence values determined in
each assay by the reference positive control. This
procedure allowed the calculation of the average normalized
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relative frequencies of each SNP allele in the studied pools.
The P. jirovecii DNA pools were analysed by MPCR/SBE in
duplicate.
Statistical analysis
As a result of the failure of the requirements for the applica-
tion of Student’s t test, the Kruskal–Wallis test was used to
analyse differences within the median Cq values of the iso-
lates that constituted pools A1, A2 and A3. Also, Kruskal–
Wallis and Mann–Whitney U tests were used to investigate
the differences between the SNP frequency distribution vari-
ation across the A1, A2 and A3 pools, and across the D and
E pools, respectively. Statistical tests were applied to investi-
gate associations at a signiﬁcance level of 0.05.
Results
DNA quantiﬁcation
In the present work a qPCR protocol was optimized for P. ji-
rovecii DNA quantiﬁcation in pulmonary specimens. This pro-
cedure was speciﬁcally directed to the P. jirovecii KEX1 gene
to guarantee the absence of interference from other DNA
sources [34,36]. The standard curve DNA concentration
versus ﬂuorescence was calculated using the ﬂuorescence
values of bacteriophage k DNA serial dilutions with known
concentrations determined by the PicoGreen quantiﬁcation
method (Fluorescence (rfu) = 12646 DNA concentration
(ng/mL) + 43049, R2 = 0.9996).
The KEX1 standard pattern serial dilutions were analysed
by the PicoGreen method and concentrations were calcu-
lated using the standard curve for DNA concentration versus
ﬂuorescence, as described above. Then, the KEX1 standard
pattern serial dilutions were studied applying the qPCR. The
dsDNA (KEX1) concentrations detected in each dilution and
the respective Cq are summarized in Table 1. The P. jirovecii
DNA pools were prepared using the standard calibration
curve for P. jirovecii KEX1 concentration against Cq values.
This standard curve equation expresses the correlation
between the concentration of P. jirovecii KEX1 gene and the
corresponding Cq in a biological sample.
DNA pooling
The average DNA concentrations and Cq values of the
pooled P. jirovecii individual samples are summarized in
Table 2. In P. jirovecii DNA pools A1, A2, A3, D and E each
sample was diluted to contribute with 1 · 10)4 ng DNA,
whereas pools B and C were prepared with 1 · 10)5 ng
DNA. The ﬁnal DNA concentration calculated for all P. ji-
rovecii pools is summarized in Table 3.
TABLE 1. DNA concentrations estimated by the PicoGreen
method and Cq values of the Pneumocystis jirovecii KEX1
standard pattern serial dilutions calculated by quantitative
PCR
KEX1 standard
pattern dilution
DNA (KEX1)
concentration (ng/mL)
Average Cq values
± standard error
1:20 614.94 11.37 ± 0.24
1:40 272.08 12.46 ± 0.12
1:103 18.07 14.53 ± 0.08
1:105 1.37 18.64 ± 0.02
1:5 · 105 0.75 21.66 ± 0.07
1:106 0.24 23.36 ± 0.08
1:5 · 106a )0.16 26.13 ± 0.05
aThe negative result presented by dilution 1:5 · 106 was not considered in fur-
ther analysis. The sensitivity limit of the PicoGreen method did not allow calcu-
lation of the DNA concentration at this dilution.
The standard calibration curve for P. jirovecii KEX1 concentration against Cq val-
ues was calculated and is represented by the equation: Cq = )3.4323 log10 KEX1
concentration (ng/mL) + 20.3610, R2= 0.9517.
Quantiﬁcation cycles (Cq) values were obtained in triplicates.
TABLE 2. Average KEX1 gene concentrations and Cq values
followed by the 95% conﬁdence intervals, calculated for the
groups of Pneumocystis jirovecii individual samples used to
compose the DNA pools
Pool
KEX1 average
concentration
(ng/mL)
Average Cq values
± standard error
95% conﬁdence
intervals
A1 0.16 34.09 ± 1.07 31.99–36.18
A2 1.51 29.21 ± 0.95 27.35–31.07
A3 2.60 26.57 ± 0.79 25.02–28.13
B 0.12 34.71 ± 0.90 32.95–36.48
C 5.41 · 10)4 36.83 ± 0.44 35.97–37.68
D 2.49 26.95 ± 0.87 25.24–28.65
E 0.45 28.97 ± 1.02 26.97–30.97
A1, AIDS-related Pneumocystis pneumonia (PcP) episodes with low parasite bur-
den; A2, AIDS-related PcP episodes with moderate parasite burden; A3, AIDS-
related PcP episodes with high parasite burden; B, HIV/P. jirovecii cases with clini-
cal course difﬁcult to interpret; C, HIV-negative patients with proven PcP epi-
sodes; D, AIDS-related PcP cases presenting positive follow-up; E, AIDS-related
PcP cases presenting negative follow-up.
According to the Kruskal–Wallis test, the average Cq values distribution of pool
A1 was statistically different from the average Cq values distribution of pools A2
(p 0.030) and A3 (p 0.001), violating the null hypothesis, in which the distribu-
tion of the Cq values should be the same across pools A1, A2 and A3.
TABLE 3. Pneumocystis jirovecii KEX1 gene ﬁnal concentra-
tions in the pools studied
Pool KEX1 concentration (ng/mL)
A1 3.35 · 10)3
A2 2.37 · 10)3
A3 3.18 · 10)3
B 0.31 · 10)3
C 0.26 · 10)3
D 2.31 · 10)3
E 4.45 · 10)3
A1, AIDS-related Pneumocystis pneumonia (PcP) episodes with low parasite bur-
den; A2, AIDS-related PcP episodes with moderate parasite burden; A3, AIDS-
related PcP episodes with high parasite burden; B, HIV/P. jirovecii cases with clini-
cal course difﬁcult to interpret; C, HIV-negative patients with proven PcP epi-
sodes; D, AIDS-related PcP cases presenting positive follow-up; E, AIDS-related
PcP cases presenting negative follow-up.
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Genotyping
With respect to pools A1, A2, A3, D and E, the three P. ji-
rovecii genetic targets (mtLSUrRNA—304 base pairs,
SOD—448 base pairs and DHFR—831 base pairs) were
simultaneously successfully ampliﬁed. However, these ampliﬁ-
cation products were not observed in the MPCRs performed
for pools B and C. Fluorescence peaks with 35 nt
(DHFR312), 47 nt (mt85), 64 nt (SOD215) and 75 nt
(SOD110) were detected in the SBE reactions performed for
MPCR products of pools A1, A2, A3, D and E. Then, the
average normalized relative frequencies of each SNP allele
were estimated (Fig. 1).
Even with a small sample size, data analysis demonstrated
several signiﬁcant statistical differences in the frequency
distribution of SNPs among pools with distinct parameters of
infection (Table 4). In those cases the distribution of the
alleles, considering the Kruskal–Wallis or the Mann–Whitney
U tests, was statistically different across the pools studied,
violating the null hypothesis. With respect to the SNP
DHFR312 frequency distribution, DHFR312T (90–100%) was
the most common allele, followed by DHFR312C (0–10%).
No statistical differences were observed in the distribution
pattern of the DHFR312 alleles across the studied pools.
Concerning the SNP mt85, the mt85A (26–62%) and mt85T
(32–55%) were the most frequent alleles, followed by mt85C
(6–23%). The difference in the distribution of mt85C across
pools A2 and A3 was statistically signiﬁcant (p 0.002). The
same was observed for the distribution pattern of mt85A
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FIG. 1. Graphic representation of Pneumocystis jirovecii single nucleotide polymorphism (SNP) allele relative frequencies distribution among the
different pools studied—A1, AIDS-related Pneumocystis pneumonia (PcP) episodes with low parasite burden; A2, AIDS-related PcP episodes with
moderate parasite burden; A3, AIDS-related PcP episodes with high parasite burden; D, AIDS-related PcP cases presenting positive follow-up; E,
AIDS-related PcP cases presenting negative follow-up). The relative frequency of each SNP was calculated dividing the maximum height values of
ﬂuorescence peaks observed in the single base extension products by the reference ﬂuorescence values observed in the positive control.
TABLE 4. Multiple comparisons of
the Pneumocystis jirovecii single
nucleotide polymorphisms fre-
quency distribution variation
across the pools studied
Pools
SNPs
DHFR312T/C mt85C mt85A mt85T SOD215C/T SOD110T/C
A1vsA2 NS NS p 0.013 p 0.020 NS NS
A1vsA3 NS NS NS NS NS NS
A2vsA3 NS p 0.002 NS NS p 0.049 p 0.049
DvsE NA p 0.002 p 0.002 p 0.041 NA NA
A1, AIDS-related Pneumocystis pneumonia (PcP) episodes with low parasite burden; A2, AIDS-related PcP episodes
with moderate parasite burden; A3, AIDS-related PcP episodes with high parasite burden; D, AIDS-related PcP cases
presenting positive follow-up; E, AIDS-related PcP cases presenting negative follow-up.
For the comparisons of the pools A1, A2 and A3, the p values presented are the adjusted p-values (Bonferroni cor-
rection) that took into consideration the number of comparisons, i.e. the Adjusted p value = p value · k(k ) 1)/2,
with k = 3 the number of pools to be compared.
NS, not signiﬁcant, p> 0.05. In these cases the distribution of the alleles, considering the Kruskal–Wallis test (A1 vs
A2; A1 vs A3; A2 vs A3), was the same across the pools studied, suggesting that the null hypothesis should be
retained.
NA, Mann–Whitney U test (D vs E) not applicable because of the small sample size of six. If the total sample size is
seven or less, the Mann–Whitney U test will always give a p value >0.05 no matter how much the groups differ.
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and mt85T across pools A1 and A2 (p 0.013 and p 0.020,
respectively). Also, a statistically signiﬁcant difference in the
distribution of the SNP mt85 was observed across pools D
and E (p 0.002 for mt85C and mt85A; p 0.041 for mt85T). In
the SOD gene allelic frequency distribution, SOD215C (52–
90%) and SOD110T (65–89%) were the most frequent alleles,
followed by SOD215T (10–48%) and SOD110C (11–35%).
The difference in the distribution of the SNPs SOD215 and
SOD110 was statistically different across pools A2 and A3
(p 0.049).
Discussion
Correlating multiple genetic differences in P. jirovecii samples
and clinical data enables the achievement of robust informa-
tion that may be used for preventing PcP [15,16,30]. In this
study, P. jirovecii DNA pools were genetically characterized
by MPCR/SBE. The potential relationships between candidate
P. jirovecii SNPs and parasite burden, clinical diagnosis and fol-
low-up of infection were evaluated. To our knowledge, the
present report is the ﬁrst study of P. jirovecii in which the
DNA pooling survey was applied.
Data analysis demonstrated statistically signiﬁcant differ-
ences between the average Cq values across pools consti-
tuted by pulmonary specimens collected from HIV-positive
patients with AIDS-related PcP presenting different levels of
parasite burden. The qPCR results corroborate the data
obtained by the semi-quantitative method (IF), showing that
qPCR is a sensitive and objective quantiﬁcation technique,
which could be used for quantiﬁcation of P. jirovecii in pulmo-
nary specimens [8,34,38]. Samples from pools B and C dem-
onstrated low average DNA concentrations (see Table 2),
which corroborates the fact that these pulmonary specimens,
especially those from pool C (HIV-negative patients), tend to
demonstrate lower parasite burdens [9]. These low concen-
trations inﬂuenced the ﬁnal amount of DNA contribution
from each sample. Hence, whereas in P. jirovecii DNA pools
A1, A2, A3, D and E each sample was diluted to contribute
with 1 · 10)4 ng DNA, pools B and C were prepared with
1 · 10)5 ng DNA. Samples from pool D (positive follow-up)
had a higher average DNA concentration than samples from
pool E (negative follow-up). This could be caused by small
sample size combined with inadequate sampling, but also it
may suggest that, in some cases, unfavourable outcome from
PcP episodes may be a consequence of insidious P. jirovecii
infections difﬁcult to diagnose because of low quantities of
parasite cells in the host lungs or even because of the pres-
ence of more virulent P. jirovecii genotypes that inﬂict a
higher severity of infection albeit at low concentrations. In
further studies, serial pulmonary specimens should be exam-
ined in this group of patients to assess the evolution of the
parasite burden levels during the course of infection, and
correlate it with the PcP clinical progress.
The allelic frequency distribution analysis revealed that
DHFR312T was the most prevalent DHFR allele, as has been
found in recent studies [11,14,16]. DHFR312T was associated
previously with PcP cases presenting moderate to high para-
site burden [30]. However, in the present work, no statisti-
cally signiﬁcant differences were observed in the allelic
frequency distribution of this SNP among the pools studied.
The allelic frequency distribution of the SNP mt85
revealed that mt85C was more frequent among pools A1 and
A2, suggesting that this allele is probably related to PcP epi-
sodes presenting low to moderate parasite burden. Also,
previous studies on Portuguese subjects showed that low to
moderate parasite burden was more frequently observed
among pulmonary specimens with mt85C and that this allele
was associated with undiagnosed or atypical PcP cases and
favourable follow-up [16,30]. Nevertheless, in the present
study mt85C was statistically more common in pool E and
less frequent in pool D, which suggests that mt85C is proba-
bly associated with unfavourable follow-up. Considering the
relationship between lower levels of parasite burden and
negative follow-up discussed above, mt85C may be related to
P. jirovecii infections characterized by a difﬁcult to diagnose
insidious clinical presentation, which could contribute to bad
clinical outcome of PcP episodes. Further studies involving a
larger sample size and pulmonary specimens from different
geographical regions should be conducted to clarify the rela-
tionship between mt85C and the follow-up of the infection.
The allele mt85A was more common among pools A2, A3
and D, suggesting that mt85A is probably associated with PcP
cases presenting moderate to high parasite burden and posi-
tive follow-up. Despite being associated with higher parasite
burdens, mt85A proves to be quite common among PcP epi-
sodes with favourable clinical outcome. These data suggest
that mt85A may be associated with P. jirovecii organisms with
relatively high replication rates but that inﬂict low severity of
infection, or even that this allele may be associated with P. ji-
rovecii infections characterized by moderate to high parasite
burden fulﬁlling the typical clinical parameters for PcP and
easier to diagnose. The allele mt85T was more frequent in
pools prepared with samples presenting low or high parasite
burden (A1 and A3, respectively). The MPCR/SBE-DNA
pooling demonstrated that mt85T was associated with PcP
episodes presenting negative follow-up (E), suggesting that
this allele may be associated with P. jirovecii organisms that
inﬂict a higher severity of infection, regardless of parasite
burden levels. Nucleotide variation of the mtLSUrRNA gene
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at base 85 may inﬂuence secondary structures of the mito-
chondrial rRNA, thereby having potential impact on ribo-
somal conformation and activity [16,30,39].
The incidence of mt85C was lower than reported in previ-
ous studies. The frequency of mt85C ranged between 6% and
23% in the present study, whereas in other studies on Portu-
guese patients the frequencies of this allele ranged between
46% and 51%. Other reports from different geographical
regions have also revealed an mt85C frequency higher than
that of the present report (e.g. 43% in Great Britain, 44% in
USA and 50–58% in Spain) [7,9,11,30–32]. This may be a
consequence of different sampling, which despite random
selection may have different characteristics between pulmo-
nary specimens and/or the fact that experimental conditions
inherent to the multiplex-SBE methodology used may inter-
fere with signal capture of the cytosine ﬂuorochrome
(ddCTP-D2) at the mt85C site during reaction. As a conse-
quence of the limited sample volume, we were not able to
repeat the MPCR/SBE DNA-pooling assay. Yet, this possible
interference does not have an impact on the allelic frequency
distribution variation analysis between the pools studied.
This probable occurrence echoed proportionally in all SBE
reactions, which validates the results obtained.
With respect to the allelic frequency distribution of P. ji-
rovecii SOD SNPs, the present results revealed that SOD215C
and SOD110T were more common in pools A1 and A2,
whereas SOD215T and SOD110C were more frequent in
pool A3. These results suggested a potential association
between SOD215C/SOD110T and low to moderate parasite
burden, as well as between SOD215T/SOD110C and high par-
asite burden. The differences observed could be because
these SNP combinations may integrate distinct P. jirovecii
organisms with different replication rates as a result of asso-
ciation with haplotypes involving other functional non-synon-
ymous polymorphisms, or as a consequence of allele-speciﬁc
differences in mRNA folding that could inﬂuence the splicing
process, or translational control and regulation of the pro-
tein [15,30,40,41]. The present data support the fact that
SNPs at bases 110 and 215 of the SOD locus may be in link-
age disequilibrium, as suggested previously [11,13,16,30].
The present study showed that the ampliﬁcation of P. ji-
rovecii genomic DNA in a multiplex format associated with
SBE genotyping and DNA pooling is a suitable high-through-
put methodology for large-scale P. jirovecii clinically relevant
SNP screening. The SNPs associated with distinct parasite
burden levels and/or severity of PcP episodes (e.g. mt85,
SOD215 and SOD110) were shown to be promising candi-
date markers to be used in MPCR/SBE protocols designed
for molecular characterization of P. jirovecii organisms. Fur-
ther studies involving a larger sample size and pulmonary
specimens from different geographical regions are required
to conﬁrm the clinical relevance of these genetic variations
and to evaluate the utility of these molecular techniques for
prognostic classiﬁcation of P. jirovecii infection to help clinical
decision-making in the management of PcP cases.
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